Miltefosine (Impavido) - FDA-Approved Oral Medication for Leishmaniasis

Miltefosine is a groundbreaking oral antileishmanial medication (commonly known as Impavido), representing the first and only FDA-approved oral treatment for certain forms of leishmaniasis — a serious parasitic disease transmitted by sandflies.

This innovative alkylphosphocholine compound effectively targets visceral leishmaniasis (affecting internal organs), cutaneous leishmaniasis (affecting the skin), and mucosal leishmaniasis, offering a convenient alternative to traditional injectable therapies. Administered as capsules, it disrupts parasite cell membranes and vital processes, delivering high efficacy rates in clinical use.

Key features:

• Oral administration for easier patient compliance
• Proven effectiveness against Leishmania species
• WHO-recognized essential medicine for neglected tropical diseases

Note: Miltefosine is a prescription pharmaceutical requiring medical supervision due to potential side effects and specific contraindications (e.g., pregnancy). Always consult a healthcare professional for proper diagnosis and treatment.